Discover and read the best of Twitter Threads about #4Humanity
Most recents (3)
The #4Humanity phase 3 trial of Sinopharm's Beijing & Wuhan vaccines published in JAMA by @NawalAlKaabi &co jamanetwork.com/journals/jama/… HT @swiftshoes
WIV04 = Wuhan: efficacy 14 days+ after dose 2, 72.8% (58-82)
HB02 = Beijing: 78.1% (65-86)
Control group was vax adjuvant ...1/n
WIV04 = Wuhan: efficacy 14 days+ after dose 2, 72.8% (58-82)
HB02 = Beijing: 78.1% (65-86)
Control group was vax adjuvant ...1/n
...Wuhan vax 12,743; Beijing 12,726; control 12,737. Just under 16% were women, <2% were aged 60 & over
Primary efficacy outcome (in tweet 1) was symptomatic Covid-19: 26 in Wuhan group, 21 in Beijing, 95 in control.
Severe Covid-19: 0 in vaxed groups, 2 in control group ...2/n
Primary efficacy outcome (in tweet 1) was symptomatic Covid-19: 26 in Wuhan group, 21 in Beijing, 95 in control.
Severe Covid-19: 0 in vaxed groups, 2 in control group ...2/n
...The trial protocol and statistical analysis plan are included as supplements
Protocol: cdn.jamanetwork.com/ama/content_pu…
SAP: https://t.co/O67m8Nf7Tn
...3/n
Protocol: cdn.jamanetwork.com/ama/content_pu…
SAP: https://t.co/O67m8Nf7Tn
...3/n
Sinopharm's presentation on their Beijing vaccine to WHO's expert committee is now online: cdn.who.int/media/docs/def… 1/n HT @AlejandrodeBar1
...Includes this overview of preclinical toxicity studies. (Note, they've also published this study on some preclinical work tandfonline.com/doi/full/10.10…) ...2/n
...The phase 3, #4Humanity trial in the Middle East - here are the blood collections taken across all the countries. (No answer here to the question of whether there were regular tests for Covid-19 in the UAE part of the trial)...3/n
Data & Safety Monitoring Board for phase 3 trial of Sinopharm's vaccines in Peru - about 12,000 people, 2 vaccines vs placebo - has recommended discontinuation of the Wuhan vaccine arm for inadequate efficacy (*not* the Beijing vax in use globally) ...1/n cayetano.edu.pe/cayetano/es/no…
...The university running the trial have sought the permission of the drug regulator to unblind participants & offer the volunteers in the Wuhan & placebo arms vaccination with the Beijing vaccine which did meet efficacy criteria (results aren't ready for release though)...2/n
...Sinopharm recently issued a press release saying the Wuhan vaccine efficacy rate was 75%. They applied to NMPA (China's drug regulator for authorization). NMPA authorized it on Feb 27 ...3/4 english.nmpa.gov.cn/2021-02/27/c_5…
